Columbia University Irving Medical Center

COVID-19 One-Step Saliva Test Is Born in Columbia Fertility Clinic

Newswise — NEW YORK, NY (June 18, 2020)—Researchers at the Columbia University Fertility Center have developed a rapid, one-step diagnostic test that detects SARS-CoV-2, the virus that causes COVID-19, in samples of saliva. The test has a single tube that contains all of the materials needed to get reliable results in about 30 minutes.

Unlike commercially available tests, the new saliva test does not require expensive instruments or proprietary components.

The test was adapted from technology currently used by Columbia fertility experts to look for genetic abnormalities in embryos prior to implantation. 

“This technology was initially developed to make a real difference to our fertility clinic patients, who need rapid, reliable test results to determine the next steps in their fertility treatment,” says Zev Williams, MD, the Wendy D. Havens Associate Professor of Women’s Health and chief of the division of reproductive endocrinology at Columbia University Irving Medical Center. “We realized that the same technology that we use to help create lives could be repurposed to help save lives during the COVID-19 pandemic. The test serves a critical need for more widespread testing to help us safely reopen economies closed by the pandemic and prevent future outbreaks.”


What’s new about this test

Current polymerase chain reaction (PCR) diagnostic tests for COVID-19 must be shipped to a reference laboratory unless the facility collecting the samples has purchased costly and proprietary machinery and cartridges to extract the SARS-CoV2 virus’s RNA from the fluid in which the sample — either a nasopharyngeal swab or saliva — is placed.

With the new test, saliva is collected in a cup and then placed into a tube containing enzymes and reagents that detect the virus’s RNA. The tube is then placed into a water bath or heat block to keep the sample warm throughout the reaction. Within 30 minutes, the fluid in the tube turns yellow if the virus’s RNA is present and red if the virus isn’t present.


Technology overcomes obstacles of testing in saliva 

The new test is based on modifications of a well-known DNA amplification technique called loop-mediated isothermal amplification (LAMP), which has several advantages for point-of-care testing for SARS-CoV2, but is >1000 times more sensitive than the traditional LAMP test in saliva. While the traditional PCR methodology used to amplify DNA requires a costly and complex thermocycler (a machine that changes temperature during different steps of the process), the LAMP test is performed at a single temperature, so it can be processed using only a heat block or water bath. In addition, the test result can be seen with the unaided eye using colorimetry.

Compounds found in saliva, and the usual buffers, enzymes, and detergents added during LAMP processing, reduce the sensitivity of the tests. Williams’ team found that alternate buffers and enzymes — along with modifications to the chemicals that recognize the virus — dramatically improved the test’s sensitivity in saliva.

The new test is based on the researchers’ LAMP test that detects the SARS-CoV-2 virus in nasal swabs. Similar to the saliva test, the nasal swab test detects the virus’s RNA directly from the transport media (the fluid in which the swab is placed before processing) in one step and does not require expensive instruments or proprietary components.


New test is reliable, scalable

Williams and other researchers at CUIMC tested the LAMP saliva assay in 60 samples, including 30 samples with virus and 30 without, and in samples from 18 patients whose saliva was also tested using RNA extraction and RT-PCR.

Their study showed that the new test correctly identified all of the negative samples that also tested negative with the Roche 6800 PCR system, resulting in 100% specificity. The test also correctly identified 29 out of 30 positive samples, resulting in overall sensitivity (a measure of a test’s ability to capture positive results) of 97% with no cross-reactivity with 19 other viruses and bacteria known to cause respiratory illness — including other coronaviruses.

The new test can detect as few as 1 or 2 copies of the virus in a microliter of saliva. Using traditional LAMP assays, even hundreds of copies of the virus wouldn’t be detected.

Williams and his team are currently seeking regulatory approval to begin using this test with patients.

“To help stem future outbreaks, diagnostic testing must be widespread and frequent. The tests themselves need to be rapid and easy to use in the field,” says Williams.

“Once we obtain regulatory approval, we envision the test being used to screen people before they board an airplane, visit a nursing home, or go to school or summer camp. The test could also be a more affordable option for health care facilities in developing countries where outbreaks have overwhelmed their testing and logistical capabilities.”


More information

The study, titled “Field-deployable, rapid and direct diagnostic testing of saliva samples for SARS-CoV-2,” was published in MedRxiv on June 16, 2020.

Other authors (all from Columbia University Irving Medical Center) are Shan Wei, Esther Kohl, Alexandre Djandji, Stephanie Morgan, Susan Whittier, Mahesh Mansukhani, Raymond Yeh, Eldad Hod, Juan Carlos Alejandre, Elaine Fleck, Mary D’Alton, and Yousin Suh.




Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit or

Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Showing results

110 of 4573